Albuterol
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Albuterol: Repurposing Evaluation Incomplete — No Predictions Available
One-Sentence Summary
Albuterol (international nonproprietary name; known as salbutamol in many markets) is a short-acting beta-2 adrenergic agonist widely used for bronchospasm and asthma. However, the TxGNN pipeline returned no predicted new indications for this candidate, and critical data fields — including mechanism of action, safety warnings, and Singapore regulatory records — could not be retrieved. This report serves as a data-gap notice; a full repurposing evaluation cannot be completed until the gaps below are resolved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this Evidence Pack |
| Predicted New Indication | No prediction available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model produced no output) |
| Singapore Market Status | Not marketed (per query result) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No predicted indication is available in this Evidence Pack; therefore, a mechanism-to-indication bridge analysis cannot be performed.
Additionally, detailed mechanism of action data was not retrieved during this pipeline run. Based on publicly available pharmacological knowledge, albuterol is a selective beta-2 adrenoceptor agonist that relaxes bronchial smooth muscle, but this background context alone is insufficient to anchor a repurposing hypothesis without a TxGNN-scored candidate indication to evaluate.
Singapore Market Information
No Singapore (HSA) drug registrations were found for "ALBUTEROL" in this query. This may reflect a nomenclature mismatch — albuterol is listed as salbutamol in most international pharmacopoeias and regulatory databases outside North America. A re-query using "SALBUTAMOL" is recommended before drawing conclusions about local market status.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction pipeline returned no candidate indications, and two blocking data gaps (TFDA/HSA package insert warnings and mechanism of action) remain unresolved. There is no actionable repurposing hypothesis to evaluate at this stage.
To proceed, the following is needed:
- Re-query with correct INN: Re-run the full pipeline using "SALBUTAMOL" (the WHO-INN) instead of "ALBUTEROL" to retrieve HSA registrations, TFDA package insert data, and TxGNN predictions correctly.
- Retrieve MOA from DrugBank: The DrugBank query returned 1 result (query log ID 2); extract the mechanism of action, pharmacological category, and drug interactions from that record.
- Retrieve safety data: Download and parse the TFDA package insert PDF to populate key warnings and contraindications (resolves DG001 — currently Blocking severity).
- Re-run TxGNN prediction: Once the drug is correctly identified and mapped, re-execute the KG and DL prediction steps to generate scored candidate indications.
- Confirm Singapore market status: After re-querying with "SALBUTAMOL", confirm HSA registration count and approved indications to assess local regulatory baseline.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.